Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: Implications for folate intake recommendations

Lancet

Volumn 349, Issue 9065, 1997, Pages 1591-1593

  Molloy, Anne M ^a   Daly, Sean ^b   Mills, James L ^d   Kirke, Peadar N ^c   Whitehead, Alexander S ^a   Ramsbottom, Dorothy ^a   Conley, Mary R ^d   Weir, Donald G ^a   Scott, John M ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b Emer Casey Molecular Pathology Research Laboratory   (Ireland)

^c HEALTH RESEARCH BOARD   (Ireland)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID;

ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; ERYTHROCYTE LEVEL; FEMALE; FOLIC ACID BLOOD LEVEL; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; HYPERHOMOCYSTEINEMIA; NEURAL TUBE DEFECT; NORMAL HUMAN; PREGNANCY; PRIORITY JOURNAL; REFERENCE VALUE; RISK; THERMOSTABILITY; VASCULAR DISEASE;

EID: 0030955502     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)12049-3     Document Type: Article

References (20)

1. Kang SS, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48: 536-45.
2. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-13.
3. de Franchis R, Sebastio G, Mandato C, Andria G, Mastroiacovo P. Spina bifida, 677T→C mutation and role of folate. Lancet 1995; 346: 1703.
4. Kirke PN, Mills JL, Whitehead AS, Molloy A, Scott JM. Methylenetetrahydrofolate reductase mutation and neural tube defects. Lancet 1996; 348: 1037-38.
5. Kang SS, Passen EL, Ruggie N, Wong PWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1993; 88: 1463-69.
6. Engbersen AMT, Franken DG, Boers GHJ, Stevens EMB, Trijbels FJM, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56: 142-50.
7. Kluijtmans LAJ, van den Heuvel LPW, Boers GHJ, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
8. Whitehead AS, Gallagher P, Mills JL, et al. A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects. Q J Med 1995; 88: 763-66.
9. van der Put NMJ, Steegers-Theunissen RPM, Frosst P, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 346: 1070-71.
10. Kang SS, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-21.
11. O'Broin S, Kelleher B. Microbiological assay on microtitre plates of folate in serum red cells. J Clin Pathol 1992; 45: 344-47.
12. 12 are independent risk factors for neural tube defects. Q J Med 1993; 86: 703-08.
13. Smith CAD, Gough AD, Leigh PN, et al. Dibrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339: 1375-77.
14. Visy JM, LeCoz P, Chadefaux B, et al. Homocysteinuria due to 5,10 methylenetetrahydrofolate reductase deficiency revealed by stroke in adult siblings. Neurology 1991; 41: 1313-15.
15. 4PteGlu reductase deficiency. J Clin Invest 1979; 63: 1019-25.
16. Baumgartner ER, Stokstad ELR, Wick H, Watson JE, Kusano G. Comparison of folic acid coenzyme distribution patterns in patients with methylenetetrahydrofolate reductase and methionine synthetase deficiencies. PediatrRes 1985; 19: 1288-92.
17. Chanarin I. The megaloblastic anaemias, 3rd edn. Oxford: Blackwell Scientific, 1990.
18. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049-57.
19. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
20. Daly LE, Kirke PN, Molloy AM, Weir DG, Scott JM. Folate levels and neural tube defects: implications for prevention. JAMA 1995; 274: 1698-702.